TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Key challenges and best practice recommendations in pregnant patients with MPN

Featured:

Claire HarrisonClaire Harrison

Jul 5, 2022

Learning objective: After reading this article, learners will be able to cite a new development in rare MPN and MPN in special populations.


The MPN Hub was pleased to speak to Claire Harrison, Guy's and St Thomas' NHS Foundation Trust, London, UK. We asked, what are the key challenges and best practice recommendations in pregnant patients with myelodysplastic syndromes (MPN)?

Key challenges and best practice recommendations in pregnant patients with MPN

Harrison begins by discussing why pregnancy can cause problems in patients with MPN, and which types of MPN are most common in these patients. Harrison also discusses the importance of planning pregnancy in advance, and the use of anticoagulants.